trending Market Intelligence /marketintelligence/en/news-insights/trending/ibpusxbuk9n2mh7amjiqvw2 content esgSubNav
In This List

Scynexis prices $30M public offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Scynexis prices $30M public offering

SCYNEXIS Inc. priced an offering of shares to raise about $30 million in gross proceeds.

The Jersey City, N.J.-based company, which develops drugs for treating infections, will sell 17,751,500 shares at $1.69 each to raise the funds. The shares will come with two separate series of warrants to buy up to an additional 21,301,800 stock of the company.

Series 1 warrants for the purchase of up to 13,313,625 shares will be priced at $1.85 each, while series 2 warrants for up to 7,988,175 shares will be exercisable for $2 apiece.

The common shares and warrants will be issued separately, with the warrants in each series exercisable immediately upon issuance.

Guggenheim Securities LLC is acting as the sole book-running manager. Needham & Co. LLC is acting as lead manager, and H.C. Wainwright & Co. LLC, Roth Capital Partners LLC, CIM Securities LLC and National Securities Corp. are acting as co-managers for the offering.